High-dose ganciclovir eye drops for CMV eye infection
Part of Eyes & vision, Infections clinical trials.
This early-phase study tests high-concentration ganciclovir eye drops to treat cytomegalovirus (CMV) retinitis, a serious eye infection. It may help people who are hard to treat with regular (systemic) antiviral medicine or who face higher risks with an injection directly into the eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must choose to join and sign an informed consent form
- You must be between ages 2 and 80
- You have CMV retinitis that fits one of these situations: after stem cell/cord blood transplant, or CMV retinitis with advanced HIV/AIDS
- Your recent blood counts must not be too low (not severe neutropenia or severe thrombocytopenia)
- You cannot have recent injections into the eye of ganciclovir (or similar) within 1 week before starting
- Your eye condition must allow doctors to see the retina well and you can’t have certain other eye diseases that affect vision
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether antiviral medicine can control eye inflammation caused by the cytomegalovirus (CMV). It has two parts: one for people with active inflammation and one for those whose inflammation has calmed down, to see if the medicine helps prevent it from coming back.
This trial tests whether valganciclovir, an antiviral medicine, can help people with advanced HIV who have CMV in their blood but no CMV disease. The goal is to see if the medicine can reduce the amount of CMV and improve health.
This study tests whether a personalized dose of the antiviral drug ganciclovir can better treat CMV infection in children with weakened immune systems. It aims to make the treatment more effective and safer for each child.
This trial tests two ways to prevent CMV in kidney transplant patients who are at high risk. It compares giving antiviral medicine preemptively (based on regular blood tests) versus giving it as prophylaxis (starting right after transplant). The goal is to see which approach prevents CMV infection better.
This study tracks how well ganciclovir (an antiviral medicine) works in transplant recipients who develop a resistant CMV infection. Researchers will review medical records to understand treatment success and patient outcomes.
This trial tests a new treatment made from your own immune cells (called LB-DTK-CMV) for a type of CMV eye infection that is not getting better with standard antiviral drugs. The goal is to see if these cells can safely control the infection and improve your vision.
Hear when a new Cytomegalovirus Retinitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.